🇺🇸 TachoSil in United States
155 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 155
Most-reported reactions
- Off Label Use — 44 reports (28.39%)
- Drug Ineffective — 30 reports (19.35%)
- Cerebrospinal Fluid Leakage — 13 reports (8.39%)
- Intestinal Obstruction — 11 reports (7.1%)
- Product Adhesion Issue — 11 reports (7.1%)
- Pyrexia — 11 reports (7.1%)
- Abdominal Abscess — 10 reports (6.45%)
- Abdominal Pain — 9 reports (5.81%)
- Haematoma — 8 reports (5.16%)
- Post Procedural Haemorrhage — 8 reports (5.16%)
TachoSil in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TachoSil approved in United States?
TachoSil does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for TachoSil in United States?
GATT Technologies BV is the originator. The local marketing authorisation holder may differ — check the official source linked above.